1. Home
  2. CVKD

as of 07-17-2026 2:15pm EST

$2.30
$0.03
-1.29%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Founded: 2022 Country:
United States
United States
Employees: N/A City: PONTE VEDRA
Market Cap: 10.3M IPO Year: 2022
Target Price: $13.00 AVG Volume (30 days): 71.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: semi-annual
EPS: -1.04 EPS Growth: 23.94
52 Week Low/High: $2.29 - $14.64 Next Earning Date: 05-08-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -2.22 Index: N/A
Free Cash Flow: -12606770.0 FCF Growth: N/A

AI-Powered CVKD Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 74.67%
74.67%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Cadrenal Therapeutics Inc. (CVKD)

Pham Quang X

Chairman and CEO

Sell
CVKD Jun 29, 2026

Avg Cost/Share

$3.03

Shares

7,400

Total Value

$22,422.00

Owned After

98,589

SEC Form 4

Pham Quang X

Chairman, CEO and Interim CFO

Sell
CVKD Jun 23, 2026

Avg Cost/Share

$3.20

Shares

2,277

Total Value

$7,286.40

Owned After

98,589

SEC Form 4

Pham Quang X

Chairman, CEO and Interim CFO

Sell
CVKD Jun 22, 2026

Avg Cost/Share

$3.55

Shares

9,167

Total Value

$32,542.85

Owned After

98,589

SEC Form 4

Pham Quang X

Chairman, CEO and Interim CFO

Sell
CVKD Jun 17, 2026

Avg Cost/Share

$3.16

Shares

513

Total Value

$1,621.08

Owned After

98,589

SEC Form 4

Pham Quang X

Chairman, CEO and Interim CFO

Sell
CVKD Jun 16, 2026

Avg Cost/Share

$3.18

Shares

3,613

Total Value

$11,489.34

Owned After

98,589

SEC Form 4

Pham Quang X

Chairman, CEO and Interim CFO

Sell
CVKD Jun 15, 2026

Avg Cost/Share

$3.58

Shares

3,666

Total Value

$13,124.28

Owned After

98,589

SEC Form 4

Pham Quang X

Chairman, CEO and Interim CFO

Sell
CVKD Jun 12, 2026

Avg Cost/Share

$3.94

Shares

12,996

Total Value

$51,204.24

Owned After

98,589

SEC Form 4

Pham Quang X

Chairman, CEO and Interim CFO

Sell
CVKD Jun 11, 2026

Avg Cost/Share

$4.12

Shares

1,462

Total Value

$6,023.44

Owned After

98,589

SEC Form 4

Pham Quang X

CEO and Chairman

Sell
CVKD Jun 2, 2026

Avg Cost/Share

$4.46

Shares

349

Total Value

$1,556.54

Owned After

98,589

SEC Form 4

Pham Quang X

CEO and Chairman

Sell
CVKD May 29, 2026

Avg Cost/Share

$5.01

Shares

303

Total Value

$1,518.03

Owned After

98,589

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-2.41%

$5.88

5D

-5.33%

$5.70

20D

-8.97%

$5.48

Price: $6.02 Prob +5D: 0% AUC: 1.000
0001213900-26-053075

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784333246.425805bf

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q4

Q4 2025 Earnings

8-K

Mar 31, 2026

0001213900-26-036937

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784333248.42582c2c

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q3

Q3 2025 Earnings

8-K SELL

Nov 10, 2025 · 100% conf.

AI Prediction SELL

1D

-4.25%

$11.26

Act: +5.02%

5D

-6.96%

$10.94

Act: -0.51%

20D

-12.94%

$10.24

Act: -15.22%

Price: $11.76 Prob +5D: 0% AUC: 1.000
0001213900-25-107949

false 0001937993

0001937993

2025-11-10 2025-11-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 10, 2025

Cadrenal Therapeutics, Inc.

(Exact name of registrant as specified in charter)

Delaware

001-41596

88-0860746

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS

Employer

Identification No.)

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

(Address of principal executive offices and zip code)

(904) 300-0701

(Registrant’s telephone number including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols

Name of each exchange on which registered

Common Stock, par value $0.001 per share

CVKD

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:

Exhibit

Number

Exhibit Description

99.1

Press Release, issued by Cadrenal Therapeutics, Inc. on November 10, 2025

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 10, 2025

CADRENAL

THERAPEUTICS, INC.

By: /s/ Quang X. Pham

Name: Quang X. Pham

Title: Chairman and Chief Executive Officer

2

Share on Social Networks: